Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.

Item
http://www.wikidata.org/entity/Q39056189
Overexpression of Wnt5a promotes angiogenesis in NSCLC.Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis.Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cellsPD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.A killer choice for cancer immunotherapy.Immunotherapy and lung cancer: current developments and novel targeted therapies.Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.VEGF as a potential target in lung cancer.Newly developed anti-angiogenic therapy in non-small cell lung cancer.
P2860

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.

Item
http://www.wikidata.org/entity/Q39056189
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
type
label
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
prefLabel
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
Bevacizumab improves the antit ...... small cell lung cancer models.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Bevacizumab improves the antit ...... small cell lung cancer models.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P921